.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,040,559

« Back to Dashboard

Details for Patent: 9,040,559

Title:BETA2-adrenoceptor agonists
Abstract: Compounds of formula ##STR00001## in free or salt or solvate form, where Ar is a group of formula ##STR00002## Y is carbon or nitrogen and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
Inventor(s): Cuenoud; Bernard (Horsham, GB), Bruce; Ian (Horsham, GB), Fairhurst; Robin Alec (Horsham, GB), Beattie; David (Horsham, GB)
Assignee: Novartis AG (Basel, CH)
Filing Date:Aug 04, 2014
Application Number:14/450,692
Claims:1. A capsule that contains a pharmaceutical composition comprising: (A) (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one or a salt or solvate thereof; (B) an anticholinergic or antimuscarinic agent; and (C) a pharmaceutically acceptable carrier.

2. A capsule according to claim 1, in which (A), (B) and (C) contained therein are in inhalable form.

3. A capsule according to claim 2, in which the pharmaceutical composition contained therein is a dry powder formulation.

4. A capsule according to claim 3 that contains a daily dose of (A) and a daily dose of (B).

5. A capsule according to claim 4, in which the daily dose of (A) is from 1 .mu.g to 5000 .mu.g.

6. A capsule according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate.

7. A capsule according to claim 5, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate.

8. A capsule according to claim 1, in which (B) is selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide.

9. A capsule according to claim 8, in which (B) is tiotropium bromide.

10. A capsule according to claim 4, in which (B) is selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide.

11. A capsule according to claim 10, in which (B) is tiotropium bromide.

12. A capsule according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate and (B) is selected from the group consisting of ipratropium bromide, oxitropium bromide and tiotropium bromide.

13. A capsule according to claim 1, in which (A) is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quin- olin-2-one maleate and (B) is tiotropium bromide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc